Survodutide vs Tirzepatide: Glucagon vs GIP Pathways

Introduction

Survodutide and tirzepatide are both dual-agonist weight loss drugs, but they hit different second targets: survodutide pairs GLP-1 with glucagon, while tirzepatide pairs GLP-1 with GIP. That single difference shapes how each drug burns fat, protects the liver, and feels day to day. Tirzepatide is approved and widely used. Survodutide is still in late-stage trials and is not yet something you can get a prescription for.

This guide breaks down the two pathways, the trial numbers behind them, and what the glucagon-versus-GIP question actually means for someone trying to lose weight.

At TrimRx, we think understanding the mechanism behind your options is the first real step toward a plan that lasts. If you want to see whether a personalized program fits your situation, the free assessment quiz is a low-pressure place to start.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is Survodutide and How Does It Work?

Survodutide (development code BI 456906) is a once-weekly injectable that activates two receptors: the GLP-1 receptor and the glucagon receptor. It is being developed by Boehringer Ingelheim and Zealand Pharma. The GLP-1 arm suppresses appetite and slows gastric emptying, the same mechanism behind semaglutide. The glucagon arm is the twist.

Quick Answer: Survodutide is a GLP-1 and glucagon receptor dual agonist still in phase 3 trials; tirzepatide (Zepbound®, Mounjaro®) is an approved GLP-1 and GIP dual agonist.

Glucagon is usually thought of as the hormone that raises blood sugar. But glucagon receptor agonism also increases energy expenditure and pushes the liver to burn stored fat. By combining appetite suppression with a metabolic rate bump, survodutide aims to drive weight loss from two directions at once.

It is still investigational. As of 2026 it has not received FDA approval for obesity, and you cannot get it through a telehealth program or a pharmacy.

What Is Tirzepatide and How Does It Work?

Tirzepatide is an approved once-weekly injectable sold as Zepbound® for weight loss and Mounjaro® for type 2 diabetes. It activates the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor.

GLP-1 does the appetite work. GIP is the part researchers spent years arguing about, because in the lab GIP seemed to do contradictory things depending on context. In practice, the GLP-1 plus GIP combination produced some of the largest weight loss numbers ever seen in obesity trials.

Tirzepatide reached the market first, has years of safety follow-up, and is one of the two molecules TrimRX offers in compounded form alongside semaglutide.

Glucagon vs GIP: What Is the Real Difference?

The core difference is the second hormone each drug recruits. Both use GLP-1 to cut appetite. Survodutide adds glucagon to raise energy expenditure and target liver fat. Tirzepatide adds GIP, which appears to improve how the body handles fat and may reduce nausea compared with GLP-1 alone.

Think of it this way. GLP-1 lowers how much you eat. GIP smooths out the metabolic side and may improve tolerability. Glucagon, by contrast, tries to raise how much energy you burn and aggressively mobilizes liver fat.

That makes survodutide especially interesting for fatty liver disease, where reducing hepatic fat is the goal. It also means the two drugs may produce different side effect profiles, since glucagon’s effect on blood sugar and heart rate has to be balanced carefully during dosing.

How Much Weight Do They Cause People to Lose?

Tirzepatide has the stronger published record. In SURMOUNT-1 (Jastreboff 2022, NEJM), adults with obesity lost about 20.9% of body weight at the 15 mg dose over 72 weeks. That trial set a high bar for the entire field.

Survodutide’s phase 2 obesity trial, published in 2024, reported mean weight reductions in the high-teens percentage range at 46 weeks, with some participants still climbing because the dose was being titrated. Reported figures landed around 19% at the top dose, though the trial design and duration differ from SURMOUNT-1, so direct comparison is rough.

The honest read: tirzepatide has proven, large, long-duration results. Survodutide looks competitive in early data but has not finished phase 3, so its real-world weight loss number is not settled.

What About Liver Disease and MASH?

This is where survodutide stands out. Its glucagon component drives the liver to burn fat, which makes it a strong candidate for MASH (metabolic dysfunction-associated steatohepatitis), formerly called NASH.

In a phase 2 MASH trial published in 2024 (NEJM), survodutide led to significant improvement in liver disease in a large share of participants compared with placebo. Reported response rates for MASH improvement without worsening of fibrosis were notably higher than placebo across doses.

Tirzepatide has also shown liver fat reduction in substudies, including data tied to its diabetes and obesity programs. But survodutide’s glucagon mechanism gives it a more direct shot at the liver, and that may end up being its defining advantage if approved.

What Are the Side Effects of Each?

Both drugs share the GLP-1 side effect family: nausea, vomiting, diarrhea, constipation, and reduced appetite. These tend to be worst during dose escalation and ease over time.

Survodutide’s glucagon arm adds a few wrinkles. Glucagon can raise heart rate and influence blood sugar, so trials have watched those signals carefully and used slow titration to manage them. Some survodutide participants reported higher rates of gastrointestinal effects during rapid dose increases, which is part of why dosing schedules matter.

Tirzepatide’s side effect profile is well characterized after years of use. Most people tolerate it with a gradual dose ramp. Serious effects are uncommon but include pancreatitis risk and gallbladder issues, which apply across the GLP-1 class.

Key Takeaway: Phase 2 survodutide data showed up to roughly 19% body weight reduction at 46 weeks; tirzepatide hit about 20.9% at the top dose in SURMOUNT-1 over 72 weeks.

Which One Preserves Muscle Better?

Neither drug is built to spare muscle, and that is a real concern with any rapid weight loss. When you lose weight fast, some of it comes from lean mass unless you actively protect it.

There is a theory that glucagon agonism could favor fat loss over lean loss because it pushes fat oxidation, but this has not been proven to translate into better muscle retention in humans. It remains a hypothesis.

For now, the muscle-protection playbook is the same regardless of drug: hit a high protein target, do resistance training two to three times a week, and avoid crash-level calorie deficits. Our muscle preservation guides cover the specifics.

When Will Survodutide Be Available?

Survodutide is in phase 3 trials as of 2026, with obesity and MASH programs running in parallel. Phase 3 readouts and regulatory review take time, so a realistic approval window is later in the decade rather than immediately.

That means if you are choosing a treatment today, survodutide is not on the menu. Tirzepatide is. The pipeline is exciting, but pipeline drugs do not help someone who wants to start now.

Survodutide vs Tirzepatide at a Glance

Tirzepatide is the proven, available choice with the largest published weight loss numbers and a long safety track record. Survodutide is the promising challenger with a unique glucagon mechanism and standout liver disease data, but it is still investigational.

If your priority is starting an evidence-backed program today, tirzepatide is the realistic option. If you are watching the field for the next breakthrough, survodutide is one of the names to follow, especially for fatty liver disease.

Your Path Forward with TrimRx

If you are weighing real options rather than pipeline promises, tirzepatide is available now, and TrimRX offers it as a compounded medication alongside semaglutide through a personalized telehealth program. Compounded tirzepatide is not the brand product and no equivalency claim is made, but it gives access to the same active molecule under provider supervision.

The practical move is to talk to a clinician about your goals, your liver and metabolic health, and how to protect muscle while you lose fat. TrimRX’s free assessment quiz is built to start that conversation and see whether a structured plan fits you.

Bottom line: As of 2026, survodutide is not approved or available. Tirzepatide is approved and is one of the medications TrimRX offers in compounded form.

FAQ

Is Survodutide Better Than Tirzepatide for Weight Loss?

Not on current evidence. Tirzepatide has proven, large, long-duration weight loss results from SURMOUNT-1, while survodutide’s strong phase 2 numbers still need phase 3 confirmation. Tirzepatide is also the only one of the two you can actually get.

What Is the Main Mechanistic Difference?

Both activate the GLP-1 receptor to cut appetite. Survodutide adds glucagon receptor activation to raise energy expenditure and burn liver fat. Tirzepatide adds GIP receptor activation, which may improve tolerability and fat handling.

Is Survodutide Good for Fatty Liver Disease?

Its phase 2 MASH data are among the most promising in the field, thanks to the glucagon component that mobilizes liver fat. It is being developed specifically for MASH as well as obesity, but it is not yet approved.

Does Survodutide Cause More Side Effects Than Tirzepatide?

Both share GLP-1 gastrointestinal effects. Survodutide’s glucagon arm can raise heart rate and affect blood sugar, so trials use slow titration to manage tolerability. Tirzepatide’s profile is better characterized after years of real-world use.

Can I Buy Survodutide Now?

No. As of 2026 survodutide is in phase 3 trials and has no FDA approval for obesity. It is not available through any pharmacy or telehealth program.

What Can I Take Instead While Survodutide Is in Trials?

Tirzepatide and semaglutide are both approved and available, including in compounded forms through telehealth programs like TrimRX. They have years of data behind them and can be started now under medical supervision.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.